secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001213900-23-047180
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax realigns board classes: Ruskin moves to Class I; quorum cut to 34%
-------------------------------------------------------------------------

- Director Barbara Ruskin resigned from Class III and was appointed to Class I, effective June 5, 2023.
- Her term now extends to the 2025 annual meeting (previously 2024).
- Bylaws amended to reduce quorum requirement to 34% of voting power at stockholder meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023047180/0001213900-23-047180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023047180/ea179780-8k_virpaxpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-047180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer